Stemline Therapeutics Inc. (NASDAQ:STML) traded down 2.7% during trading on Wednesday . The company traded as low as $9.61 and last traded at $9.81, with a volume of 70,302 shares traded. The stock had previously closed at $10.08.

A number of research analysts have recently issued reports on STML shares. Roth Capital reiterated a “buy” rating and set a $32.00 target price on shares of Stemline Therapeutics in a research report on Thursday, June 9th. Jefferies Group reiterated a “buy” rating and set a $23.00 target price on shares of Stemline Therapeutics in a research report on Monday, June 6th. Wedbush reiterated an “outperform” rating and set a $16.00 target price on shares of Stemline Therapeutics in a research report on Tuesday, June 7th. Finally, Zacks Investment Research lowered Stemline Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 12th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Stemline Therapeutics has an average rating of “Buy” and an average target price of $19.31.

The firm’s 50-day moving average price is $8.15 and its 200 day moving average price is $6.73. The stock’s market cap is $181.99 million.

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.03. Stemline Therapeutics had a negative return on equity of 44.59% and a negative net margin of 4,419.18%. Equities research analysts forecast that Stemline Therapeutics Inc. will post ($2.11) earnings per share for the current fiscal year.

A number of large investors have recently made changes to their positions in the company. State Street Corp raised its stake in shares of Stemline Therapeutics by 3.3% in the first quarter. State Street Corp now owns 216,571 shares of the biopharmaceutical company’s stock valued at $1,008,000 after buying an additional 6,884 shares in the last quarter. Royce & Associates LP raised its stake in shares of Stemline Therapeutics by 9.4% in the first quarter. Royce & Associates LP now owns 174,179 shares of the biopharmaceutical company’s stock valued at $812,000 after buying an additional 15,000 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Stemline Therapeutics by 15.3% in the first quarter. Renaissance Technologies LLC now owns 79,100 shares of the biopharmaceutical company’s stock valued at $369,000 after buying an additional 10,500 shares in the last quarter. Franklin Resources Inc. raised its stake in shares of Stemline Therapeutics by 16.8% in the first quarter. Franklin Resources Inc. now owns 1,880,030 shares of the biopharmaceutical company’s stock valued at $8,761,000 after buying an additional 270,700 shares in the last quarter. Finally, BlackRock Fund Advisors raised its stake in shares of Stemline Therapeutics by 0.4% in the first quarter. BlackRock Fund Advisors now owns 406,268 shares of the biopharmaceutical company’s stock valued at $1,893,000 after buying an additional 1,724 shares in the last quarter. Institutional investors own 52.42% of the company’s stock.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

5 Day Chart for NASDAQ:STML

Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.